))
The Latest News and Notes, plus Conversation with Wiley A. Chambers, MD
Manage episode 409228423 series 3560279
Content provided by Healio, John Hovanesian, MD, FACS, and Jim Mazzo. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Healio, John Hovanesian, MD, FACS, and Jim Mazzo or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
In this episode, John A. Hovanesian, MD, FACS, and Jim Mazzo discuss the latest news in eye care and chat with Wiley A. Chambers, MD, about his career in the FDA and his plans for retirement.
Brought to you by Johns Hopkins University
- Welcome to the Eyeluminaries podcast :21
- Review of episode 21 :50
- Clobetasol propionate ophthalmic suspension 0.05% approved for postop inflammation, pain 2:49
- PulseSight Therapeutics launches with focus on non-viral gene therapies 5:31
- FDA clears first investigational new drug application for neuropathic corneal pain 7:59
- APX3330 ‘promising’ oral treatment option for slowing progression of diabetic retinopathy 10:20
- H. Dunbar Hoskins Jr., decorated glaucoma specialist, dies 11:55
- Intro of Wiley A. Chambers, MD 13:36
- What are you most proud of accomplishing in your 36 years at the FDA? 15:54
- What about oral therapies for the eye? 17:30
- What do you wish you could change? 18:46
- What advice would you give an innovator with a new drug idea? 21:31
- What’s next for Wiley Chambers? Ocular Advisors, LLC 23:17
- What has changed since you left the FDA? 25:11
- Second annual drug name awards: The Year of Vs and Ys 27:04
- “Needs to buy a vowel” award 28:49
- “i before e” award 30:23
- “Most likely to be misspelled” award 31:44
- “Is there a way to pay for it?” award 33:17
- The cutesy award 34:29
- “Need an award” award 36:10
- Preview of episode 23 38:17
- Feedback, questions and guest suggestions at eyeluminaries@healio.com 39:59
- Thanks for listening 39:36
John A. Hovanesian, MD, FACS, is a faculty member at the UCLA Jules Stein Eye Institute and in private practice at Harvard Eye Associates in Laguna Hills, California.
Jim Mazzo is an ophthalmic industry veteran with over 40 years as CEO/Chairman of both public and private companies, including Allergan, Avellino Labs, Carl Zeiss, Neurotech Pharmaceuticals and AMO. Additionally, he is an advisor for Bain Capital and CVC Capital Partners and sits on numerous industry boards such as MDMA.
Wiley A. Chambers, MD, is a clinical professor of ophthalmology and adjunct assistant professor of computer medicine at The George Washington University and owner of Ocular Advisors, LLC.
We’d love to hear from you! Send your comments/questions to eyeluminaries@healio.com. Follow John Hovanesian on X (formerly Twitter) @DrHovanesian.
Disclosures: Chambers is the owner of Ocular Advisors, LLC. Hovanesian consults widely in the ophthalmic field. Mazzo reports being an adviser for Zeiss, Bain Capital, Avellino Labs, CVC Capital, Anivive Lifesciences; executive chairman of Neurotech, Preceyes BV and TearLab; and sits on the board of Crystilex, Lensgen, IanTech, Centricity Vision and Visus.
27 episodes
Share
